Julio F Marchini1, Wilton F Gomes1, Bruno Moulin1, Marco A Perin1, Ludmilla A R R Oliveira1, J Airton Arruda1, Valter C Lima1, Antonio A G Lima1, Paulo R A Caramori1, Cesar R Medeiros1, Mauricio R Barbosa1, Fabio S Brito1, Expedito E Ribeiro1, Pedro A Lemos1. 1. 1 Heart Institute (InCor), University of São Paulo Medical School (USP), São Paulo, Brazil ; 2 Hospital Universitário Cassiano Antonio de Moraes, Vitória, Brazil ; 3 Hospital Santa Marcelina, São Paulo, Brazil ; 4 Natal Hospital Center, Natal, Brazil ; 5 Hospital Meridional, Vitória, Brazil ; 6 Federal University of São Paulo (UNIFESP-EPM), São Paulo, Brazil ; 7 Hospital Universitário Walter Cantidio, Fortaleza, Brazil ; 8 Hospital São Lucas - PUC-RS, Porto Alegre, Brazil ; 9 Rede D'Or de Hospitais, Rio de Janeiro, Brazil ; 10 Hospital Biocor, Belo Horizonte, Brazil ; 11 São Camilo Hospital, São Paulo, Brazil.
Abstract
BACKGROUND: Few studies have examined the very long-term outcomes after implantation of drug-eluting stents (DES) coated with biodegradable polymers (BP). This report presents the 5-year clinical follow-up of patients treated with BP-DES in the randomized PAINT trial. METHODS: The PAINT study is a prospective, multicenter randomized controlled trial that allocated 274 patients for treatment with twoBP-DES formulations [paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES)] or bare metal stents (BMS) in a 1:2:2 ratio, respectively. The primary end-point of this sub-study was defined as the composite of the major cardiac adverse events (MACE) cardiac death, myocardial infarction (MI) or ischemia-driven target vessel revascularization (TVR) at 5 years. RESULTS: The 5-year MACE rates were different among the groups: 35.3%, 22.5% and 16.9% for BMS, PES and SES, respectively (P<0.05 for both DES vs. bare stent comparisons). The primary end-point was mainly driven by TVR: 31.8%, 14.1% and 12.2% for bare stents, PES and SES, respectively (P<0.05 for both DES vs. bare stent comparisons). The incidence of stent thrombosis (ST) was null for BMS during the entire follow-up. There was no definite or probable ST in the SES group after the second year, while one patient (1.0%) presented with a definite ST episode in the PES group between 4 and 5 years. CONCLUSIONS: The tested biodegradable-polymer coated stents releasing either paclitaxel or sirolimus, compared with same bare metal platform, sustained their effectiveness in reducing combined major adverse cardiac events and re-intervention without an increase in ST during 5 years of follow-up.
RCT Entities:
BACKGROUND: Few studies have examined the very long-term outcomes after implantation of drug-eluting stents (DES) coated with biodegradable polymers (BP). This report presents the 5-year clinical follow-up of patients treated with BP-DES in the randomized PAINT trial. METHODS: The PAINT study is a prospective, multicenter randomized controlled trial that allocated 274 patients for treatment with two BP-DES formulations [paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES)] or bare metal stents (BMS) in a 1:2:2 ratio, respectively. The primary end-point of this sub-study was defined as the composite of the major cardiac adverse events (MACE) cardiac death, myocardial infarction (MI) or ischemia-driven target vessel revascularization (TVR) at 5 years. RESULTS: The 5-year MACE rates were different among the groups: 35.3%, 22.5% and 16.9% for BMS, PES and SES, respectively (P<0.05 for both DES vs. bare stent comparisons). The primary end-point was mainly driven by TVR: 31.8%, 14.1% and 12.2% for bare stents, PES and SES, respectively (P<0.05 for both DES vs. bare stent comparisons). The incidence of stent thrombosis (ST) was null for BMS during the entire follow-up. There was no definite or probable ST in the SES group after the second year, while one patient (1.0%) presented with a definite ST episode in the PES group between 4 and 5 years. CONCLUSIONS: The tested biodegradable-polymer coated stents releasing either paclitaxel or sirolimus, compared with same bare metal platform, sustained their effectiveness in reducing combined major adverse cardiac events and re-intervention without an increase in ST during 5 years of follow-up.
Authors: Ian T Meredith; Stefan Verheye; Neil J Weissman; Paul Barragan; Douglas Scott; Mariano Valdés Chávarri; Nick E J West; Henning Kelbæk; Robert Whitbourn; Darren L Walters; Jacek Kubica; Leif Thuesen; Monica Masotti; Adrian Banning; Iwar Sjögren; Rod H Stables; Dominic J Allocco; Keith D Dawkins Journal: EuroIntervention Date: 2013-07 Impact factor: 6.534
Authors: Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani Journal: J Am Coll Cardiol Date: 2006-05-05 Impact factor: 24.094
Authors: Giulio G Stefanini; Robert A Byrne; Patrick W Serruys; Antoinette de Waha; Bernhard Meier; Steffen Massberg; Peter Jüni; Albert Schömig; Stephan Windecker; Adnan Kastrati Journal: Eur Heart J Date: 2012-03-24 Impact factor: 29.983
Authors: Pedro A Lemos; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro; Eulógio E Martinez Journal: Arq Bras Cardiol Date: 2009-12 Impact factor: 2.000
Authors: Jonathan R Nebeker; Renu Virmani; Charles L Bennett; Jennifer M Hoffman; Matthew H Samore; Jorge Alvarez; Charles J Davidson; June M McKoy; Dennis W Raisch; Brian K Whisenant; Paul R Yarnold; Steven M Belknap; Dennis P West; Jonathan E Gage; Richard E Morse; Gordana Gligoric; Laura Davidson; Marc D Feldman Journal: J Am Coll Cardiol Date: 2005-12-01 Impact factor: 24.094
Authors: Pedro A Lemos; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro; Eulógio E Martinez Journal: Catheter Cardiovasc Interv Date: 2009-11-01 Impact factor: 2.692
Authors: Christoph Stettler; Simon Wandel; Sabin Allemann; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suarez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Anna Sonia Petronio; Alain J Nordmann; Peter Diem; Bernhard Meier; Marcel Zwahlen; Stephan Reichenbach; Sven Trelle; Stephan Windecker; Peter Jüni Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: Pedro A Lemos; Bruno Moulin; Marco A Perin; Ludmilla A R R Oliveira; J Airton Arruda; Valter C Lima; Antonio A G Lima; Paulo R A Caramori; Cesar R Medeiros; Mauricio R Barbosa; Fabio S Brito; Expedito E Ribeiro Journal: EuroIntervention Date: 2012-05-15 Impact factor: 6.534
Authors: Marcos Danillo Peixoto Oliveira; Expedito E Ribeiro; Carlos M Campos; Henrique B Ribeiro; Bruno L R Faillace; Augusto C Lopes; Rodrigo B Esper; George X Meirelles; Marco A Perin; Alexandre Abizaid; Pedro A Lemos Journal: Cardiovasc Diagn Ther Date: 2015-08